Catalent Inc (CTLT) Stock Price & Overview
NYSE:CTLT • US1488061029
Current stock price
The current stock price of CTLT is 63.48 USD. Today CTLT is down by 0%. In the past month the price increased by 8%. In the past year, price increased by 44.01%.
CTLT Key Statistics
- Market Cap
- 11.522B
- P/E
- 288.55
- Fwd P/E
- 41.25
- EPS (TTM)
- 0.22
- Dividend Yield
- N/A
CTLT Stock Performance
CTLT Stock Chart
CTLT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CTLT. When comparing the yearly performance of all stocks, CTLT is one of the better performing stocks in the market, outperforming 86.78% of all stocks.
CTLT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTLT. Both the profitability and financial health of CTLT have multiple concerns.
CTLT Earnings
On November 5, 2024 CTLT reported an EPS of -0.13 and a revenue of 1.02B. The company missed EPS expectations (-336.02% surprise) and missed revenue expectations (-5.19% surprise).
CTLT Forecast & Estimates
14 analysts have analysed CTLT and the average price target is 64.77 USD. This implies a price increase of 2.03% is expected in the next year compared to the current price of 63.48.
For the next year, analysts expect an EPS growth of 350.55% and a revenue growth 8.33% for CTLT
CTLT Groups
Sector & Classification
CTLT Financial Highlights
Over the last trailing twelve months CTLT reported a non-GAAP Earnings per Share(EPS) of 0.22. The EPS decreased by -61.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| Debt/Equity | 1.38 |
CTLT Ownership
CTLT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.94 | 865.533B | ||
| JNJ | JOHNSON & JOHNSON | 20.21 | 572.592B | ||
| MRK | MERCK & CO. INC. | 22.06 | 282.347B | ||
| PFE | PFIZER INC | 9.03 | 155.861B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.08 | 118.339B | ||
| ZTS | ZOETIS INC | 16.34 | 48.963B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.78 | 26.264B | ||
| VTRS | VIATRIS INC | 5.26 | 15.544B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.8 | 12.489B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.127B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.974B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.21B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.12 | 4.197B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CTLT
Company Profile
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 16,900 full-time employees. The company went IPO on 2014-07-31. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. The company also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. The company also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.
Company Info
IPO: 2014-07-31
Catalent Inc
14 Schoolhouse Rd
Somerset NEW JERSEY 08873 US
CEO: John R. Chiminski
Employees: 16900
Phone: 17325376200
Catalent Inc / CTLT FAQ
What does Catalent Inc do?
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 16,900 full-time employees. The company went IPO on 2014-07-31. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. The company also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. The company also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.
What is the stock price of Catalent Inc today?
The current stock price of CTLT is 63.48 USD.
What is the dividend status of Catalent Inc?
CTLT does not pay a dividend.
What is the ChartMill technical and fundamental rating of CTLT stock?
CTLT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does Catalent Inc belong to?
Catalent Inc (CTLT) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the PE ratio for CTLT stock?
The PE ratio for Catalent Inc (CTLT) is 288.55. This is based on the reported non-GAAP earnings per share of 0.22 and the current share price of 63.48 USD.
How many employees does Catalent Inc have?
Catalent Inc (CTLT) currently has 16900 employees.